Amarin Corp. (AMRN) Gets U.S. Patent for AMR101
Amarin Corporation plc (Nasdaq: AMRN), reports that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical composition of Amarin's AMR101 based on U.S. Patent Application Serial No. 12/052,598, also known as the EPA with no DHA in a capsule application. Amarin announced on March 20, 2012, the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,188,146, is titled "Highly Purified Ethyl EPA and Other EPA Derivatives."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OPKO Health (OPK) Submits Factor VIIa Phase 2a IND to U.S. FDA
- L-3 Communications (LLL) Unit Awarded Two NSA Contracts with Potential Ceiling at $1B+
- TRACON Pharmaceuticals (TCON) Prices 3.6M Common IPO at $10/Share
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!